← Leaderboards
Elizabeth R. Sharlow
Prolx Pharmaceuticals, Lp
$1,800,275
Attributed
$1,900,422
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $565.3K · FY2014–21$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
'19
'20
'21
Funding mix
By agency
NIH$1,900,422 · 3
By mechanism
R01$1,372,750 · 1
R43$377,451 · 1
R03$150,221 · 1
Top collaborators
- Mark Elliot Drew2 shared
- James Culvin Morris2 shared
Most similar at Prolx Pharmaceuticals, Lp
Same institution · by research overlap
- Lynn Kirkpatrick$9,343,688
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposPharmaceutical PreparationsSignal TransductionScreeningBaseSmall MoleculeLibrariesHigh Throughput ScreeningBrainS DiseaseNeuronsPreventMediatingInduced Pluripotent Stem CellNeuron LossSmall Molecule InhibitorCell CycleDisease ProgressionExposure ToCessation Of LifeAbeta OligomerCytokinesisFutureCells
Grant awards (8)
A Precision high content screening assay for AB-mediated neuronal cell cycle reentry$403,750
R01 · FY2021 · AG · contact PI
A Precision high content screening assay for AB-mediated neuronal cell cycle reentry$403,750
R01 · FY2020 · AG · contact PI
A Precision high content screening assay for AB-mediated neuronal cell cycle reentry$161,500
R01 · FY2020 · AG · contact PI
A Precision high content screening assay for AB-mediated neuronal cell cycle reentry$403,750
R01 · FY2019 · AG · contact PI
Probe identification by HTS for Plasmodium Falciparum Hexokinase$74,063
R03 · FY2015 · HD
Probe identification by HTS for Plasmodium Falciparum Hexokinase$76,158
R03 · FY2014 · HD
SURVIVAL SIGNALING INHIBITORS AS CANCER DRUGS$126,067
R43 · FY2002 · CA
SURVIVAL SIGNALING INHIBITORS AS CANCER DRUGS$251,384
R43 · FY2001 · CA